Back to Search
Start Over
Whole genome sequencing identifies genetic variants associated with co-trimoxazole hypersensitivity in Asians.
- Source :
-
The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2021 Apr; Vol. 147 (4), pp. 1402-1412. Date of Electronic Publication: 2020 Aug 10. - Publication Year :
- 2021
-
Abstract
- Background: Co-trimoxazole, a sulfonamide antibiotic, is used to treat a variety of infections worldwide, and it remains a common first-line medicine for prophylaxis against Pneumocystis jiroveci pneumonia. However, it can cause severe cutaneous adverse reaction (SCAR), including Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms. The pathomechanism of co-trimoxazole-induced SCAR remains unclear.<br />Objective: We aimed to investigate the genetic predisposition of co-trimoxazole-induced SCAR.<br />Methods: We conducted a multicountry case-control association study that included 151 patients with of co-trimoxazole-induced SCAR and 4631 population controls from Taiwan, Thailand, and Malaysia, as well as 138 tolerant controls from Taiwan. Whole-genome sequencing was performed for the patients and population controls from Taiwan; it further validated the results from Thailand and Malaysia.<br />Results: The whole-genome sequencing study (43 case patients vs 507 controls) discovered that the single-nucleotide polymorphism rs41554616, which is located between the HLA-B and MICA loci, had the strongest association with co-trimoxazole-induced SCAR (P = 8.2 × 10 <superscript>-9</superscript> ; odds ratio [OR] = 7.7). There were weak associations of variants in co-trimoxazole-related metabolizing enzymes (CYP2D6, GSTP1, GCLC, N-acetyltransferase [NAT2], and CYP2C8). A replication study using HLA genotyping revealed that HLA-B∗13:01 was strongly associated with co-trimoxazole-induced SCAR (the combined sample comprised 91 case patients vs 2545 controls [P = 7.2 × 10 <superscript>-21</superscript> ; OR = 8.7]). A strong HLA association was also observed in the case patients from Thailand (P = 3.2 × 10 <superscript>-5</superscript> ; OR = 3.6) and Malaysia (P = .002; OR = 12.8), respectively. A meta-analysis and phenotype stratification study further indicated a strong association between HLA-B∗13:01 and co-trimoxazole-induced drug reaction with eosinophilia and systemic symptoms (P = 4.2 × 10 <superscript>-23</superscript> ; OR = 40.1).<br />Conclusion: This study identified HLA-B∗13:01 as an important genetic factor associated with co-trimoxazole-induced SCAR in Asians.<br /> (Copyright © 2020 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)
- Subjects :
- Adolescent
Adult
Aged
Case-Control Studies
Female
Humans
Malaysia epidemiology
Male
Middle Aged
Polymorphism, Single Nucleotide
Taiwan epidemiology
Thailand epidemiology
Whole Genome Sequencing
Young Adult
Anti-Bacterial Agents adverse effects
Anti-Infective Agents, Urinary adverse effects
Asian People genetics
Drug Hypersensitivity genetics
Genetic Predisposition to Disease
HLA-B Antigens genetics
Trimethoprim, Sulfamethoxazole Drug Combination adverse effects
Subjects
Details
- Language :
- English
- ISSN :
- 1097-6825
- Volume :
- 147
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- The Journal of allergy and clinical immunology
- Publication Type :
- Academic Journal
- Accession number :
- 32791162
- Full Text :
- https://doi.org/10.1016/j.jaci.2020.08.003